Acton Pharmaceuticals, Inc. to Be Acquired by Meda for Up to $200 Million

  Acton Pharmaceuticals, Inc. to Be Acquired by Meda for Up to $200 Million

Business Wire

MARLBOROUGH, Mass. -- August 30, 2013

Acton Pharmaceuticals, Inc., a specialty respiratory pharmaceutical company,
today announced that it has entered into a definitive agreement under which
the Company will be acquired by Meda in an all cash transaction. The proposed
transaction is subject to customary regulatory approvals and standard closing

Under the terms of the agreement, Meda will acquire 100% of Acton’s shares for
$135 million plus $10 million in a contingent, near-term development
milestone. Acton will also receive certain sales-based milestones, which may
bring the total potential acquisition value up to $200 million.

Acton  is focused on the development of respiratory medicine and recently
received U.S. Food and Drug Administration approval for AEROSPAN™
(flunisolide), for the treatment of asthma. AEROSPAN is a HFA-propelled
inhaled corticosteroid (ICS) and is the only approved HFA inhaler in its class
to incorporate a built-in spacer device, which assists in the delivery of the
medicine to the lungs. The value of the U.S. single-entity ICS market is
approaching $2 billion with more than 12 million prescriptions written each

AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for
the maintenance treatment of asthma as prophylactic therapy in adult and
pediatric patients 6 years of age and older.

Acton was founded in March 2008 by John Simon, Chief Executive Officer and
Daniel Kreisler, President & Chief Operating Officer of Acton.

"Through this transaction with Meda, AEROSPAN will now be commercialized by a
company with one of the leading respiratory focused sales forces in the U.S.,”
commented Daniel Kreisler. “We strongly believe this will accelerate the
prescribing of this unique inhaled steroid product so we can achieve our goal
of making AEROSPAN one of the leading therapies in the $2 billion U.S. inhaled
steroid market.”

John Simon continued, “We are excited to enter into this agreement with Meda,
a leading global pharmaceutical company. Meda’s experience marketing
respiratory products combined with their significant track record of success
makes them extremely well-suited to launch AEROSPAN to respiratory and
pediatric physicians in the U.S.”

Scott Carter, a partner at Sequoia Capital and a member of Acton’s Board of
Directors said, “We are very fortunate to partner with Acton Pharmaceuticals.
Sequoia Capital recognizes and applauds the excellence of this highly
experienced management team who has driven the company to tremendous success.”

Barclays is acting as financial advisor and Bingham McCutchen LLP is acting as
legal advisor to Acton in the transaction.

About Sequoia Capital

Since 1972, Sequoia Capital has provided early stage and growth stage venture
capital for very smart founders and executives who have turned great ideas
into sustainable companies of enduring value. As the "Entrepreneurs Behind the
Entrepreneurs", Sequoia Capital's Partners have worked with accomplished
innovators and operators who built great franchises such as Ameritox, Amylin
Pharmaceuticals, Apple Computer, Cisco Systems, CV Therapeutics, eCardio
Diagnostics, Flextronics, Google, Network Appliance, nVidia, Oracle, PayPal,
Therasense, Yahoo!, YouTube and Zappos. To learn more about Sequoia Capital

About Acton Pharmaceuticals

Acton is a specialty respiratory pharmaceutical company dedicated to
developing prescription drugs to improve the well-being of patients. Acton's
corporate headquarters are located in Marlborough, Massachusetts. To learn
more about Acton visit,

About Meda AB

Meda AB is leading international specialty pharma company. Meda’s products are
sold in more than 120 countries worldwide and the company is represented by
its own organizations in over 55 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more,

AEROSPAN is a trademark of Forest Laboratories, Inc.


Acton Pharmaceuticals, Inc.
Daniel L. Kreisler, 508-329-3146
Press spacebar to pause and continue. Press esc to stop.